RANCHO CUCAMONGA, Calif., Aug. 02, 2017 -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2017, ended June 30, 2017, after the market closes on Wednesday, August 9, 2017, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll free (877) 881-2595, or (315) 625-3083 for international callers, five minutes before the conference. The passcode for the conference call is 62348267.
The call can also be accessed on the Investors page on the Company’s website www.amphastar.com.
Amphastar is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation products, including products with high technical barriers to market entry. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.
Forward Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding future financial performance, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, acquisitions and other matters related to its pipeline of product candidates, its share buyback program and other future events. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations and other similar or related factors. Words such as “may,” “might”, “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission. You can locate these reports through the Company’s website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. Amphastar undertakes no obligation to revise or update information in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause the Company’s expectations to change.
Contact: William J. Peters Chief Financial Officer (909) 476-3416


U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Italy Fines Apple €98.6 Million Over App Store Dominance
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 



